These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 25841712)

  • 1. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
    Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
    J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T
    Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
    Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
    Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT for Staging; Past, Present, and Future.
    El-Galaly TC; Gormsen LC; Hutchings M
    Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S; Shah H; Jacene H
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
    Makita S; Maruyama D; Maeshima AM; Taniguchi H; Yuda S; Toyoda K; Yamauchi N; Fukuhara S; Munakata W; Kobayashi Y; Kurihara H; Izutsu K; Tobinai K
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):108-114. PubMed ID: 31802636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised staging system for malignant lymphoma based on the Lugano classification.
    Munakata W; Terauchi T; Maruyama D; Nagai H
    Jpn J Clin Oncol; 2019 Oct; 49(10):895-900. PubMed ID: 31504700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
    Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
    El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
    J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
    Schwenzer NF; Pfannenberg AC
    Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
    El-Galaly TC; Hutchings M
    Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PET in lymphoma.
    Schwaiger M; Wieder H
    Chang Gung Med J; 2005 May; 28(5):315-25. PubMed ID: 16086546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.